FrancophonIA/ELRC3.0 huggingface dataset:
English: Active renal secretion of lamivudine in the urine is mediated through the organic cation transporter (OCT) 2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K).
Slovenian: Aktivno ledvično izločanje lamivudina v urinu posreduje organski kationski prenašalec (OCT) 2 ter prenašalci za ekstruzijo več zdravil in toksinov (MATE1 in MATE-2K).
English: In dolutegravir Phase III studies patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN).
Slovenian: V študijah faze III z dolutegravirjem so bolniki s sočasno okužbo z virusom hepatitisa B in/ali C smeli biti vključeni v študijo pod pogojem, da njihove izhodiščne vrednosti jetrnih testov niso presegle petkratne zgornje meje normale (ULN - upper limit of normal).
English: § Includes reasons such as withdrew consent, loss to follow-up, moved, protocol deviation.
Slovenian: § Vključuje razloge, kot so umik soglasja, prenehanje spremljanja, preselitev, odstopanje od protokola.
English: Although abacavir and lamivudine are substrates of BCRP and P-gp in vitro, given the high absolute bioavailability of abacavir and lamivudine, (see section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on abacavir or lamivudine concentrations.
Slovenian: Čeprav sta abakavir in lamivudin in vitro substrata BCRP in P-gp, glede na njuno veliko absolutno biološko uporabnost (glejte poglavje 5.2) ni verjetno, da bi zavrtje teh efluksnih prenašalcev klinično pomembno vplivalo na koncentracijo abakavirja ali lamivudina.
English: Co-administration of Triumeq and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may therefore increase dolutegravir plasma concentration.
Slovenian: Sočasno jemanje zdravila Triumeq in drugih zdravil, ki zavirajo UGT1A1, UGT1A3, UGT1A9, CYP 3A4 in/ali P-gp, lahko zato poveča plazemske koncentracije dolutegravirja.
English: Triumeq is recommended to be administered 2 hours before or 6 hours after taking supplements or multivitamins containing calcium, iron or magnesium (see section 4.5).
Slovenian: Zdravilo Triumeq je priporočljivo vzeti 2 uri pred ali 6 ur po uporabi dodatkov ali multivitaminskih pripravkov, ki vsebujejo kalcij, železo ali magnezij (glejte poglavje 4.5).
English: No Triumeq dosage adjustment necessary, unless patient has renal impairment (See Section 4.2).
Slovenian: Odmerka zdravila Triumeq ni potrebno prilagajati, razen če ima bolnik okvaro ledvic (glejte poglavje 4.2).
English: If you have stopped taking Triumeq for any reason - especially because you think you are having side effects, or because you have another illness:
Slovenian: Če ste zdravilo Triumeq prenehali jemati zaradi kakršnega koli razloga - še zlasti če menite, da imate neželene učinke, ali ker imate kako drugo bolezen:
English: Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever.
Slovenian: Skoraj vsi bolniki, ki bodo razvili preobčutljivostne reakcije, bodo imeli v sklopu tega sindroma povišano telesno temperaturo in/ali izpuščaj (običajno makulopapularni ali urtikarijski), vendar pa so se pojavile tudi reakcije brez izpuščaja ali povišane telesne temperature.
English: What Triumeq looks like and contents of the pack Triumeq film-coated tablets are purple, biconvex, oval tablets, debossed with “572 Trı” on one side.
Slovenian: Izgled zdravila Triumeq in vsebina pakiranja Filmsko obložene tablete zdravila Triumeq so vijolične, bikonveksne, ovalne tablete z vtisnjeno oznako ‘572 Trı' na eni strani.
English: 48 weeks DTG 50 mg + ABC/3TC once daily N=414
Slovenian: 48 tednov DTG 50 mg + ABC/3TC enkrat na dan N=414
English: rash, pruritus, alopecia1
Slovenian: izpuščaj, srbenje, alopecija
English: Similar reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).
Slovenian: Podobne reakcije po ponovni uvedbi abakavirja so se redkeje pojavile tudi pri bolnikih z enim samim ključnim simptomom preobčutljivosti (glej zgoraj) pred ukinitvijo abakavirja, v zelo redkih primerih pa tudi pri bolnikih, pri katerih je bila brez predhodnih simptomov preobčutljivosti terapija uvedena ponovno (tj. pri bolnikih, za katere je predhodno veljalo, da prenašajo abakavir).
English: Contact your doctor immediately: 1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups: fever shortness of breath, sore throat or cough nausea or vomiting, diarrhoea or abdominal pain severe tiredness or aches and pains, or generally feeling ill.
Slovenian: Takoj se posvetujte z zdravnikom: 1 če se vam pojavi izpuščaj na koži ALI 2 če se vam pojavijo simptomi iz vsaj 2 od naslednjih skupin: povišana telesna temperatura zasoplost, boleče žrelo ali kašelj siljenje na bruhanje ali bruhanje, driska ali bolečine v trebuhu huda utrujenost ali bolečine ali splošno slabo počutje.
English: The safety and efficacy of Triumeq has not been established in patients with significant underlying liver disorders.
Slovenian: Varnosti in učinkovitosti zdravila Triumeq pri bolnikih s pomembnimi osnovnimi motnjami v delovanju jeter niso dokazali.
English: Triumeq should not be taken with any other medicinal products containing dolutegravir, abacavir, lamivudine or emtricitabine.
Slovenian: Zdravila Triumeq se ne sme jemati s katerim koli drugim zdravilom, ki vsebuje dolutegravir, abakavir, lamivudin ali emtricitabin.
English: - The other ingredients are mannitol (E421), microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, magnesium stearate, poly(vinyl) alcohol - partially hydrolysed, titanium dioxide, macrogol/PEG, talc, iron oxide black and iron oxide red).
Slovenian: - Druge sestavine so: manitol (E421), mikrokristalna celuloza, povidon (K29/32), natrijev karboksimetil škrob, magnezijev stearat, poli(vinil) alkohol - delno hidroliziran, titanov dioksid, makrogol/PEG, smukec, črni železov oksid in rdeči železov oksid.
English: Patients with chronic hepatitis B or C
Slovenian: Bolniki s kroničnim hepatitisom B ali C
English: If Triumeq is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis.
Slovenian: Če se pri bolnikih, sočasno okuženih s hepatitisom B, zdravljenje z zdravilom Triumeq prekine, je priporočljivo periodično spremljati tako teste delovanja jeter kot tudi označevalce replikacije virusa HBV, saj lahko ukinitev lamivudina vodi v akutno poslabšanje hepatitisa.
English: Lamivudine-TP (an analogue for cytidine) and carbovir-TP (the active triphosphate form of abacavir, an analogue for guanosine) are substrates for and competitive inhibitors of HIV reverse transcriptase (RT).
Slovenian: Lamivudin-TP (analog citidina) in karbovir-TP (aktivna trifosfatna oblika abakavirja, analog gvanozina) sta substrata za reverzno transkriptazo (RT) virusa HIV in tudi njena kompetitivna inhibitorja.
English: GlaxoSmithKline Pharmaceuticals S.A., UL.Grunwaldzka 189, 60-322 Poznan, Poland
Slovenian: GlaxoSmithKline Pharmaceuticals S.A., UL.Grunwaldzka 189, 60-322 Poznan, Poljska
English: DTG/ABC/3TC FDC - abacavir/dolutegravir/lamivudine fixed-dose combination ATV+RTV+TDF/FTC FDC -atazanavir plus ritonavir plus tenofovir disproxil/emtricitabine fixeddose combination
Slovenian: DTG/ABC/3TC FDC - kombinacija fiksnih odmerkov abakavirja/dolutegravirja/lamivudina ATV+RTV+TDF/FTC FDC - kombinacija fiksnih odmerkov atazanavirja in ritonavirja in dizoproksiltenofovirata/emtricitabina
English: If you forget to take Triumeq
Slovenian: Če ste pozabili vzeti zdravilo Triumeq
English: Before initiating treatment with abacavir-containing products, screening for carriage of the HLAB*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4).
Slovenian: Pred uvedbo zdravljenja z zdravili, ki vsebujejo abakavir, je pri vsakem bolniku, okuženim z virusom HIV, treba opraviti presejalni test za prisotnost alela HLA-B*5701, ne glede na rasno poreklo (glejte poglavje 4.4).
English: CPK elevations, ALT/AST elevations
Slovenian: povišane vrednosti CPK, povišane vrednosti ALT/AST
English: AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state.
Slovenian: AUC v cervikovaginalni tekočini, tkivu materničnega vratu in nožničnem tkivu je bila od 6 do 10% ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
English: Mitochondrial dysfunction following exposure in utero
Slovenian: Moteno delovanje mitohondrijev po izpostavljenosti in utero
English: Common side effects that may show up in blood tests are: • an increase in the level of liver enzymes
Slovenian: Pogosti neželeni učinki, ki se lahko pokažejo pri pregledu krvi, so: • povišana vrednost jetrnih encimov
English: The individual preparations of abacavir and lamivudine have been investigated separately, and as a dual nucleoside backbone, in combination antiretroviral therapy to treat ART- naive and ARTexperienced HIV- infected paediatric patients (data available on the use of abacavir and lamivudine in infants less than three months are limited).
Slovenian: Posamezna zdravila abakavirja in lamivudina so raziskovali posebej, in kot dvojno nukleozidno osnovo, v kombinaciji s protiretrovirusno terapijo za zdravljenje s HIV okuženimi pediatričnimi bolniki, ki predhodno še niso ali so že prejemali ART (razpoložljivi podatki o uporabi abakavirja in lamivudina pri dojenčkih, mlajših od treh mesecev, so omejeni).
English: Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration.
Slovenian: Etravirin brez okrepljenih zaviralcev proteaz je zmanjšal koncentracijo dolutegravirja v plazmi.
English: PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING INTERMEDIATE CARTON (WITHOUT BLUE BOX - COMPONENT OF MULTIPACK)
Slovenian: VMESNA ŠKATLA (BREZ »BLUE BOX« - SESTAVNEGA DELA SKUPNEGA PAKIRANJA)
English: ‡ Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.
Slovenian: ‡ Vključuje preiskovance, ki so prenehali sodelovati zaradi neželenega dogodka ali smrti kadar koli v času od 1. dne do zaključenega 48. tedna analize, če zaradi tega ni bilo nobenih viroloških podatkov o zdravljenju v obdobju analize.
English: If Triumeq is used in patients co-infected with hepatitis B an additional antiviral is, therefore, generally needed.
Slovenian: Če se zdravilo Triumeq uporablja pri bolnikih, ki so sočasno okuženi tudi s hepatitisom B, je običajno treba uporabiti še dodatno protivirusno zdravilo.
English: Dose reduction is required for patients with creatinine clearance < 50 ml/min (see section 4.2).
Slovenian: Pri bolnikih s kreatininskim očistkom < 50 ml/min je potrebno odmerek zmanjšati (glejte poglavje 4.2).
English: White HDPE (high density polyethylene) bottles closed with polypropylene child-resistant closures, with a polyethylene faced induction heat seal liner.
Slovenian: Bele plastenke iz HDPE (polietilena visoke gostote) zaprte s polipropilenskimi, z za otroke varnimi zaporkami, zapečatenimi s polietilensko folijo s pomočjo toplotne indukcije.
English: Hypersensitivity reactions have been reported in <1% of patients treated with dolutegravir in clinical studies, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
Slovenian: V kliničnih študijah poročajo o preobčutljivostnih reakcijah pri <1% bolnikov, zdravljenih z dolutegravirjem, za katere so bili značilni izpuščaj, sistemski pojavi, včasih pa tudi motnje v delovanju organov, vključno s hudimi jetrnimi reakcijami.
English: What you need to know before you take Triumeq
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Triumeq
English: 1) you get a skin rash OR
Slovenian: 1) se vam pojavi izpuščaj na koži ALI
English: • metformin, to treat diabetes
Slovenian: • metformin za zdravljenje sladkorne bolezni
English: AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.
Slovenian: AUC v semenu je bila 7% in v tkivu danke 17% ustrezne AUC v plazmi v stanju dinamičnega ravnovesja.
English: • oxcarbazepine and carbamazepine, to treat epilepsy and bipolar disorder
Slovenian: • okskarbamazepin in karbamazepin, za zdravljenje epilepsije in bipolarne motnje
English: • difficulty breathing In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders).
Slovenian: V redkih primerih, ko se imunski sistem okrepi, lahko napade tudi zdrava telesna tkiva (avtoimune bolezni).
English: • lactic acidosis (excess lactic acid in the blood).
Slovenian: • laktacidoza (čezmerno kopičenje mlečne kisline v krvi)
English: Based on the lack of effect on the in vivo pharmacokinetics of the OAT substrate tenofovir, in vivo inhibition of OAT1 is unlikely.
Slovenian: Zaradi pomanjkanja učinka na farmakokinetiko OAT substrata tenofovirja in vivo zaviranje OAT1 in vivo ni verjetno.
English: The results showed that there was a mean increase of 1.89-fold [1.32; 2.70] in the abacavir AUC, and 1.58 [1.22; 2.04] fold in the elimination half-life.
Slovenian: Rezultati so pokazali, da je bila AUC abakavirja povečana v povprečju za 1,89-krat [1,32; 2,70], eliminacijski razpolovni čas pa v povprečju za 1,58-krat [1,22; 2,04].
English: Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see sections 4.4 and 5.1).
Slovenian: Zdravilo Triumeq je indicirano za zdravljenje odraslih in mladostnikov, starejših od 12 let, ki tehtajo vsaj 40 kg, okuženih z virusom humane imunske pomanjkljivosti (HIV) (glejte poglavji 4.4 in 5.1).
English: The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose.
Slovenian: Farmakokinetične lastnosti abakavirja so preučevali pri bolnikih z blago jetrno okvaro (Child-Pugh ocena 5-6 ), ki so prejeli abakavir v enkratnem 600 mg odmerku.
English: The most severe adverse event possibly related to the treatment with dolutegravir and abacavir/lamivudine, seen in individual patients, was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4 and Description of selected adverse reactions in this section).
Slovenian: Najresnejši neželeni učinek, verjetno povezan z zdravljenjem z dolutegravirjem in abakavirjem/lamivudinom, opažen pri posameznih bolnikih, je preobčutljivostna reakcija z izpuščajem in hudo prizadetostjo jeter (glejte poglavje 4.4 in Opis izbranih neželenih učinkov v tem poglavju).
English: MATE2-K. Abacavir is therefore not expected to affect the plasma concentrations of drugs that are substrates of these enzymes or transporters.
Slovenian: Zato ni pričakovati, da bi abakavir vplival na plazemsko koncentracijo zdravil, ki so substrati teh encimov ali prenašalcev.
English: In vivo, a 10-14% decrease of creatinine clearance (secretory fraction is dependent on OCT2 and MATE-1 transport) was observed in patients.
Slovenian: In vivo so pri bolnikih opazili 10-14% zmanjšanje očistka kreatinina (sekretorna frakcija je odvisna od prenosa OCT2 in MATE-1).
English: Occasionally, hypersensitivity reactions have developed in people who start taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.
Slovenian: Občasno so se preobčutljivostne reakcije pojavile pri osebah, ki so začele ponovno jemati zdravila, ki vsebujejo abakavir, vendar so imele prej, preden so ga prenehale jemati, le enega od simptomov z Opozorilne kartice za bolnika.
English: Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see Section 4.8 Description of selected adverse reactions).
Slovenian: V redkih primerih so se pri bolnikih, ki so prenehali jemati abakavir zaradi drugih razlogov in ne zaradi simptomov preobčutljivostne reakcije, pojavile življenjsko nevarne reakcije že v nekaj urah po ponovni uvedbi zdravljenja z abakavirjem (glejte poglavje 4.8 Opis izbranih neželenih učinkov).
English: Dolutegravir was non-inferior to raltegravir, including within the subset of patients with the abacavir/lamivudine background regimen.
Slovenian: Dolutegravir je bil v primerjavi z raltegravirjem neinferioren, tudi v podskupini bolnikov, ki so v osnovni shemi prejemali abakavir/lamivudin.
English: • if they are overweight.
Slovenian: • če imajo prekomerno telesno maso
English: • presence of skin rash; OR
Slovenian: • izpuščaja na koži; ALI
English: The combination of lamivudine with cladribine is not recommended (see section 4.5).
Slovenian: Kombinacija lamivudina s kladribinom ni priporočljiva (glejte poglavje 4.5).
English: Triumeq is recommended to be administered 2 hours before or 6 hours after these medicinal products (see section
Slovenian: Zdravilo Triumeq je priporočljivo vzeti 2 uri pred ali 6 ur po uporabi teh zdravil (glejte poglavje 4.5).
English: Some lateonset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Slovenian: Redko so poročali o nekaterih primerih nevroloških motenj, ki nastopijo pozneje (hipertonija, konvulzije, nenormalno vedenje).
English: Marketing Authorisation Holder ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands.
Slovenian: Imetnik dovoljenja za promet z zdravilom ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Nizozemska
English: Mannitol (E421) Microcrystalline cellulose Povidone (K29/32) Sodium starch glycollate Magnesium stearate
Slovenian: Jedro tablete manitol (E421) mikrokristalna celuloza povidon (K29/32) natrijev karboksimetilškrob magnezijev stearat
English: Neither abacavir nor lamivudine were mutagenic in bacterial tests, but consistent with other nucleoside analogues, inhibit cellular DNA replication in in vitro mammalian tests such as the mouse lymphoma assay.
Slovenian: Niti abakavir niti lamivudin nista pokazala mutagenosti pri testih na bakterijah, vendar pa, skladno z drugimi nukleozidnimi analogi, inhibirata replikacijo celične DNK v študijah in vitro na celicah sesalcev, npr. celicah mišjega limfoma.
English: In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).
Slovenian: V metaanalizi farmakogenomskih vzorcev iz kliničnih študij zdravih preiskovancev so imele osebe z genotipi UGT1A1 (n = 7), ki povzročajo počasno presnovo dolutegravirja, 32% manjši očistek dolutegravirja in 46% večjo AUC kot preiskovanci z genotipi, ki so povezani z normalno presnovo z UGT1A1 (n = 41).
English: The effect of food on plasma exposures of abacavir and lamivudine following administration of Triumeq with a high fat meal were very similar to prior food effects observed with ABC/3TC FDC.
Slovenian: Učinek hrane na izpostavljenost abakavirju in lamivudinu v plazmi po aplikaciji zdravila Triumeq z mastnim obrokom je bil zelo podoben učinkom pri ABC/3TC FDC na tešče.
English: →Talk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with Triumeq.
Slovenian: → Posvetujte se z zdravnikom o jemanju dodatkov ali multivitaminskih pripravkov, ki vsebujejo kalcij, železo ali magnezij skupaj z zdravilom Triumeq.
English: Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.
Slovenian: Študije vezave na plazemske proteine in vitro kažejo, da se abakavir pri terapevtskih koncentracijah le slabo do zmerno (~ 49%) veže na humane plazemske proteine.
English: • sensation of weakness in the limbs
Slovenian: • občutek šibkosti v udih
English: In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).
Slovenian: V študijah toksičnosti za razmnoževanje pri živalih niso bili ugotovljeni negativni učinki na razvoj, vključno z okvarami nevralne cevi (glejte poglavje 5.3).
English: DRV+RTV 800mg + 100mg once daily +2 NRTI N=242
Slovenian: DRV+RTV 800 mg + 100 mg enkrat dnevno +2 NRTI N=242
English: The geometric mean terminal half-life of intracellular active moiety carbovirtriphosphate (TP) at steady-state is 20.6 hours.
Slovenian: Geometrični srednji končni razpolovni čas aktivne znotrajcelične oblike, karbovir trifosfata (TP), znaša v stanju dinamičnega ravnovesja 20,6 ure.
English: In vitro, abacavir was not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, MRP2 or MRP4 therefore drugs that modulate these transporters are not expected to affect abacavir plasma concentrations.
Slovenian: In vitro abakavir ni bil substrat OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, MRP2 ali MRP4, zato ni pričakovati, da bi zdravila, ki vplivajo na te prenašalce, vplivala na koncentracijo abakavirja v plazmi.
English: EFV/TDF/FTC once daily N=419
Slovenian: EFV/TDF/FTC enkrat na dan N=419
English: Both abacavir and dolutegravir are associated with a risk for hypersensitivity reactions (HSR) (see section 4.8), and share some common features such as fever and/or rash with other symptoms indicating multi-organ involvement.
Slovenian: Tako abakavir kot dolutegravir povezujejo s tveganjem za pojav preobčutljivostnih reakcij (glejte poglavje 4.8), ki imajo nekatere skupne značilnosti, kot so povišana telesna temperatura in/ali izpuščaj z drugimi simptomi, ki kažejo na prizadetost več organov.
English: Moderate amount of data (more than 600 outcomes from first trimester) indicates no malformative toxicity for abacavir.
Slovenian: Obstaja zmerna količina podatkov (več kot 600 izidov po izpostavljenosti v prvem trimesečju), ki niso pokazali malformacijske toksičnosti za abakavir.
English: Metformin is eliminated renally and therefore it is of importance to monitor renal function when co-treated with dolutegravir.
Slovenian: Metformin se izloča skozi ledvice, zato je med sočasnim zdravljenjem z dolutegravirjem pomembno kontrolirati delovanje ledvic.
English: The adjusted mean change in CD4+ T cell count from baseline were 267 cells versus 208 cells/mm3, respectively (p<0.001).
Slovenian: Prilagojena povprečna sprememba vrednosti CD4 + T celic od izhodiščne vrednosti je bila 267 celic proti 208 celic/mm
English: Even patients who don't have the HLAB*5701 gene may still develop a hypersensitivity reaction, described in this leaflet in the panel headed ‘Hypersensitivity reactions'.
Slovenian: Celo bolniki, ki nimajo gena HLA-B*5701, lahko vseeno razvijejo preobčutljivostno reakcijo, ki je opisana v tem navodilu pod naslovom »Preobčutljivostne reakcije«.
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Slovenian: Pri bolnikih s HIV, ki imajo ob uvedbi kombinirane protiretrovirusne terapije (CART-combination antiretroviral therapy) hudo imunsko pomanjkljivost, se lahko pojavi vnetna reakcija na asimptomatske ali rezidualne oportunistične patogene in povzroči resne klinične zaplete ali poslabšanje simptomov.